"新創團隊的活力取決於產業鏈，我們致力於建立一個強大的生態系統"
"身為創笙加速器的董事長，我很自豪地在這趟探索細胞和基因治療潛力無窮的旅程中，打造並培養了一群充滿遠見的企業家和科學家。我們一起在醫療保健、生物技術等領域開創了一些破壞式創新的解決方案，推動著創新，跨足界限，重新定義在生命科學領域裡什麼是可能的"
"創笙加速器將培養一種充滿創意和創新的文化，並挑戰再生醫學的極限"
James Tsai, Ph.D., boasts a remarkable track record of success. He has successfully founded and led Deesse Vivante Biomed and Unicocell Biomed to a successful public listing and OTC listing. Furthermore, he has achieved significant accomplishments in the field of clinical product development, spearheading human clinical phase I/IIa trials for allogeneic adipose mesenchymal stem cell therapy for degenerative joint diseases, with TFDA IND approvals at Chang Gung and Tri-Service General Hospitals.
In the realm of GXP, he established Taiwan’s first cell therapy PICS/GMP pilot factory and the country’s first early-stage cell therapy GTP facility, earning recognition from Japan’s PMDA for overseas CPC (cell processing center). Additionally, he obtained TAF ISO/TES 17025 certification in cell therapy and collaborated with multiple hospitals on special permit applications.
His IMPAC award in large-scale production is a testament to his achievements. He developed a semi-automated production line for adherent MSCs, obtained FDA DMF (Drug Master File) certification, and invented the first Class II medical device for automated filling and sealing of cell storage containers.
尤齊著先生過往於生技醫療領域，舉凡投資、併購、私募基金募集及成功出場等享譽業界，在元大亞洲投資擔任副總期間，展現出傑出的業績，擅長開發案源、盡職調查，以及在投資後協助新創對接合適企業。
除了在已投資的新創公司擔任董事，並在營運規畫上培育其成長動能，對協助新創募資更是不遺餘力。
尤先生深厚的市場洞察力和卓越的投資敏銳度使他成為生醫領域方面的投資專家之一。他在辨識當今動態市場中的成長機會方面的天賦，使他在輔導渴望成長的新創企業時更得心應手。
Dr. Shen is a dedicated researcher in the fields of stem cells and regenerative medicine. His work focuses on the reprogramming of somatic cells, investigating key mechanisms of cell differentiation and transformation. He has published 90 journal articles, cited nearly 3300 times. His research areas include:
Outside of research, Dr. Shen has pursued legal and technology management studies at Taiwan University and National Chengchi University. He has also been involved in various academic roles and served as an executive director. He played a key role in establishing the Taiwan Stem Cell Society and served as its first secretary-general. Additionally, he held the position of president from 2017 to 2021 and is currently an executive director of the Taiwan Cell Therapy Association and the Regenerative Medicine Society, actively involved in promoting legislation and policies related to cell therapy and planning physician training courses. Since January 2019, he has been leading the Biomedical Translation Core Facility, providing technical platforms for the biotechnology research community. From September 2019, he has served as the acting CEO of the Academia Sinica Biomedical Translation Research Center’s Innovation and Incubation Center, supporting the growth of Taiwan’s biotech startups in the national biotech research park.
王嘉嫃博士在免疫學研究、細胞治療和細胞製程相關領域擁有豐富的專業經驗。曾受聘為國防醫學院助理教授及於中研院和台大醫學院擔任博士後研究員。專攻免疫治療及臨床前新藥研發，對於藥物研發流程和臨床試驗具有深入了解。致力於細胞治療領域多年，曾擔任長庚醫院細胞治療中心研究員和品質計畫專責人員，參與GTP設施的設計和建立，及輔助許多細胞治療案件的進行。並受聘為台灣生醫品質保證協會（TSQA）GTP專家小組成員，積極參與生醫產品的品質保證工作和GXP政策討論。王博士在細胞治療技術和臨床試驗的案件申請和臨床施行方面亦有豐富的經驗，曾任長春藤生命科學臨床醫學部經理，具有卓越的臨床治療協調和專案領導能力。
George Su，畢業於聖荷西州立大學。他目前擔任Mosaic Venture Lab和CellTech Innovation Venture Studio的專案經理一職，擁有出色的溝通、問題解決和批判性思維能力。此外，他還具備戰略規劃的專業知識，以及對時間和風險管理的敏感觸覺。
Edward Chen是一位資深研究科學家，在新藥開發發領域擁有超過十年研發的成功經驗。Edward在國立台灣大學取得毒理學博士學位，專精於腫瘤學以及各種人類幹細胞，如MSC、ESC、iPSC和癌幹細胞研究。轉換跑道至生技製藥產業後，Edward致力於新藥開發、體外毒性評估、動物疾病模型建立、PK/PD動物實驗，並與全球的臨床前CRO公司密切合作。Edward熱愛挑戰，渴望將自己的專業知識貢獻給貴組織。
Patryk Chojecki is an up-and-coming professional with a master’s degree in International Affairs from National Chengchi University. In the early stages of his career, Patryk gained valuable experience as a Research Assistant at Academia Sinica, making significant contributions to projects related to the US government. Additionally, he served as a Contributing Researcher at the Taiwan Architecture & Building Center (TABC), where he forged partnerships with European companies and authored articles on governance, the economy, and ESG investing. Patryk’s passion for economics, politics, and his growing interest in future startup ventures reflect his potential to make meaningful contributions to the global biotech landscape.
王麗茹博士現為財團法人生物技術開發中心藥品商品化中心主任（2017.04~至迄今），負責藥品商品化中心整體運作，並提供技術市場分析、專利佈局和分析及技術商業化等服務，以協助學研界和業界克服藥品商品化過程中的瓶頸；先前曾前後擔任生技製藥與生技醫藥國家型科技計畫橋接計畫主持人逾11年，在推動生技醫藥商業化發展上有豐富的成果與經驗。
並且在產業實務上具有近20年專利分析、諮詢/策略、專利地圖、專利侵害鑑定等專利相關經驗，同時具有高考專利師、食品技師、營養師等國家執照；也因其擁有之豐沛的專利與商品化輔導經驗，而受聘擔任國家生技研究園區、台灣生物產業發展協會…等審查委員。
此外，她所帶領的團隊，過去10年來，為完善台灣生技產業鏈上下游之鏈結，協助學界研發成果完成技術授權簽約、產學合作計畫簽約及促成新創公司成立等技術商業化具體成果共超過80件以上，促成廠商投資超過25億新台幣等實績。
